Symbols / ALMS $21.94 -6.12% Alumis Inc.
ALMS Chart
About
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 2.79B |
| Enterprise Value | 2.70B | Income | -243.32M | Sales | 24.05M |
| Book/sh | 2.88 | Cash/sh | 2.42 | Dividend Yield | — |
| Payout | 0.00% | Employees | 221 | IPO | — |
| P/E | — | Forward P/E | -6.79 | PEG | — |
| P/S | 116.04 | P/B | 7.62 | P/C | — |
| EV/EBITDA | -6.16 | EV/Sales | 112.31 | Quick Ratio | 4.24 |
| Current Ratio | 4.34 | Debt/Eq | 12.25 | LT Debt/Eq | — |
| EPS (ttm) | -2.86 | EPS next Y | -3.23 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-15 | ROA | -73.36% |
| ROE | -86.68% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -50.67% | Profit Margin | 0.00% | Shs Outstand | 123.14M |
| Shs Float | 91.18M | Short Float | 12.86% | Short Ratio | 6.89 |
| Short Interest | — | 52W High | 30.60 | 52W Low | 2.76 |
| Beta | — | Avg Volume | 2.09M | Volume | 1.62M |
| Target Price | $38.40 | Recom | Strong_buy | Prev Close | $23.37 |
| Price | $21.94 | Change | -6.12% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-30 | main | Oppenheimer | Outperform → Outperform | $55 |
| 2026-03-30 | main | Chardan Capital | Buy → Buy | $38 |
| 2026-03-30 | main | HC Wainwright & Co. | Buy → Buy | $25 |
| 2026-03-20 | main | Morgan Stanley | Overweight → Overweight | $38 |
| 2026-03-20 | main | Chardan Capital | Buy → Buy | $38 |
| 2026-03-11 | init | Raymond James | — → Strong Buy | $46 |
| 2026-02-25 | init | Stifel | — → Buy | $44 |
| 2026-01-21 | init | Chardan Capital | — → Buy | $37 |
| 2026-01-09 | reit | HC Wainwright & Co. | Buy → Buy | $40 |
| 2026-01-07 | main | Leerink Partners | Outperform → Outperform | $32 |
| 2026-01-07 | main | Morgan Stanley | Overweight → Overweight | $33 |
| 2026-01-07 | main | Guggenheim | Buy → Buy | $32 |
| 2026-01-06 | main | Wells Fargo | Overweight → Overweight | $39 |
| 2025-12-18 | main | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-08-15 | main | Morgan Stanley | Overweight → Overweight | $22 |
| 2025-08-14 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2025-07-25 | init | Wells Fargo | — → Overweight | $17 |
| 2025-07-25 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2025-05-15 | main | Oppenheimer | Outperform → Outperform | $25 |
| 2025-04-30 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
- Alumis (NASDAQ:ALMS) Shares Down 4.1% - Here's What Happened - MarketBeat Mon, 06 Apr 2026 17
- Raymond James and Guggenheim Stay Bullish on Alumis (ALMS) After Trial Results - Insider Monkey Mon, 06 Apr 2026 21
- Alumis (ALMS) insider-linked entities shift 4.1M shares via in-kind distributions - Stock Titan Fri, 03 Apr 2026 19
- Alumis (ALMS) Valuation Check After Positive Phase 3 Psoriasis Results For Envudeucitinib - Yahoo Finance Sat, 04 Apr 2026 03
- Assessing Alumis (ALMS) Valuation After Positive Phase 3 Envudeucitinib Psoriasis Results And NDA Plans - simplywall.st Mon, 06 Apr 2026 01
- Why Alumis Inc. Stock Is Dropping After Good News - tipranks.com Mon, 06 Apr 2026 15
- Foresite entities move ALUMIS (ALMS) shares in pro rata in-kind distributions - Stock Titan Fri, 03 Apr 2026 19
- Why Alumis (ALMS) Is Down 5.8% After Positive Phase 3 Psoriasis Data And NDA Plans - Yahoo Finance Sat, 04 Apr 2026 17
- Why Alumis (ALMS) Is Down 8.4% After Positive Phase 3 Psoriasis Data And FDA Filing Plans - simplywall.st hu, 02 Apr 2026 00
- Foresite funds realign Alumis (ALMS) stakes via in-kind distributions - Stock Titan Fri, 03 Apr 2026 19
- ALMS May 2026 16.000 put (ALMS260515P00016000) Stock Price, News, Quote & History - Yahoo! Finance Canada Sat, 04 Apr 2026 11
- ALMS SEC Filings - Alumis Inc 10-K, 10-Q, 8-K Forms - Stock Titan hu, 02 Apr 2026 10
- ALMS Apr 2026 36.000 call (ALMS260417C00036000) Stock Price, News, Quote & History - Yahoo! Finance Canada Fri, 03 Apr 2026 20
- ALMS Apr 2026 17.000 call (ALMS260417C00017000) Stock Price, News, Quote & History - Yahoo! Finance Canada Fri, 03 Apr 2026 18
- Tananbaum-led funds update Alumis (ALMS) ownership and 13D stake - Stock Titan Fri, 03 Apr 2026 19
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
24.05
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
24.05
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
477.85
+58.89%
|
300.75
+90.14%
|
158.17
+38.93%
|
113.85
|
| Research And Development |
|
386.00
+45.36%
|
265.55
+92.88%
|
137.68
+35.90%
|
101.30
|
| Selling General And Administration |
|
91.86
+160.95%
|
35.20
+71.72%
|
20.50
+63.38%
|
12.55
|
| General And Administrative Expense |
|
91.86
+160.95%
|
35.20
+71.72%
|
20.50
+63.38%
|
12.55
|
| Other Gand A |
|
91.86
+160.95%
|
35.20
+71.72%
|
20.50
+63.38%
|
12.55
|
| Total Expenses |
|
477.85
+58.89%
|
300.75
+90.14%
|
158.17
+38.93%
|
113.85
|
| Operating Income |
|
-453.80
-50.89%
|
-300.75
-90.14%
|
-158.17
-38.93%
|
-113.85
|
| Total Operating Income As Reported |
|
-453.80
-50.89%
|
-300.75
-90.14%
|
-158.17
-38.93%
|
-113.85
|
| EBITDA |
|
-450.31
-51.31%
|
-297.60
-89.69%
|
-156.89
-38.11%
|
-113.60
|
| Normalized EBITDA |
|
-638.22
-118.42%
|
-292.20
-86.38%
|
-156.77
-38.00%
|
-113.60
|
| Reconciled Depreciation |
|
3.50
+10.91%
|
3.15
+145.48%
|
1.28
+413.60%
|
0.25
|
| EBIT |
|
-453.80
-50.89%
|
-300.75
-90.14%
|
-158.17
-38.93%
|
-113.85
|
| Total Unusual Items |
|
187.91
+3575.90%
|
-5.41
-4442.86%
|
-0.12
|
—
|
| Total Unusual Items Excluding Goodwill |
|
187.91
+3575.90%
|
-5.41
-4442.86%
|
-0.12
|
—
|
| Special Income Charges |
|
187.91
|
0.00
|
—
|
—
|
| Restructuring And Mergern Acquisition |
|
-187.91
|
0.00
|
—
|
—
|
| Net Income |
|
-243.32
+17.30%
|
-294.23
-89.84%
|
-154.99
-38.47%
|
-111.93
|
| Pretax Income |
|
-251.89
+14.39%
|
-294.23
-89.84%
|
-154.99
-38.47%
|
-111.93
|
| Net Non Operating Interest Income Expense |
|
14.18
+17.97%
|
12.02
+256.89%
|
3.37
+69.08%
|
1.99
|
| Net Interest Income |
|
14.18
+17.97%
|
12.02
+256.89%
|
3.37
+69.08%
|
1.99
|
| Interest Income Non Operating |
|
14.18
+17.97%
|
12.02
+256.89%
|
3.37
+69.08%
|
1.99
|
| Interest Income |
|
14.18
+17.97%
|
12.02
+256.89%
|
3.37
+69.08%
|
1.99
|
| Other Income Expense |
|
187.74
+3514.04%
|
-5.50
-2840.64%
|
-0.19
-159.72%
|
-0.07
|
| Other Non Operating Income Expenses |
|
-0.17
-81.72%
|
-0.09
-36.76%
|
-0.07
+5.56%
|
-0.07
|
| Gain On Sale Of Security |
|
—
|
-5.41
-4442.86%
|
-0.12
|
—
|
| Tax Provision |
|
-8.56
|
0.00
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
6.39
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-243.32
+17.30%
|
-294.23
-89.84%
|
-154.99
-38.47%
|
-111.93
|
| Net Income From Continuing Operation Net Minority Interest |
|
-243.32
+17.30%
|
-294.23
-89.84%
|
-154.99
-38.47%
|
-111.93
|
| Net Income From Continuing And Discontinued Operation |
|
-243.32
+17.30%
|
-294.23
-89.84%
|
-154.99
-38.47%
|
-111.93
|
| Net Income Continuous Operations |
|
-243.32
+17.30%
|
-294.23
-89.84%
|
-154.99
-38.47%
|
-111.93
|
| Normalized Income |
|
-424.84
-47.09%
|
-288.83
-86.49%
|
-154.87
-38.37%
|
-111.93
|
| Net Income Common Stockholders |
|
-243.32
+17.30%
|
-294.23
-89.84%
|
-154.99
-38.47%
|
-111.93
|
| Diluted EPS |
|
—
|
-10.38
-247.21%
|
-2.99
-2.59%
|
-2.91
|
| Basic EPS |
|
—
|
-10.38
-247.21%
|
-2.99
-2.59%
|
-2.91
|
| Basic Average Shares |
|
—
|
28.34
-45.33%
|
51.84
+34.98%
|
38.41
|
| Diluted Average Shares |
|
—
|
28.34
-45.33%
|
51.84
+34.98%
|
38.41
|
| Diluted NI Availto Com Stockholders |
|
-243.32
+17.30%
|
-294.23
-89.84%
|
-154.99
-38.47%
|
-111.93
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
411.94
+20.81%
|
340.99
+280.52%
|
89.61
-17.15%
|
108.17
|
| Current Assets |
|
318.23
+3.93%
|
306.19
+473.85%
|
53.36
-47.97%
|
102.56
|
| Cash Cash Equivalents And Short Term Investments |
|
308.50
+7.02%
|
288.26
+488.87%
|
48.95
-47.29%
|
92.86
|
| Cash And Cash Equivalents |
|
89.67
-47.11%
|
169.53
+268.57%
|
46.00
+79.60%
|
25.61
|
| Other Short Term Investments |
|
218.83
+84.30%
|
118.74
+3916.81%
|
2.96
-95.60%
|
67.25
|
| Receivables |
|
2.08
+14.96%
|
1.81
+150.97%
|
0.72
+44.40%
|
0.50
|
| Taxes Receivable |
|
0.74
-33.57%
|
1.11
+81.43%
|
0.61
+22.80%
|
0.50
|
| Accrued Interest Receivable |
|
1.34
+92.41%
|
0.70
+546.30%
|
0.11
|
—
|
| Prepaid Assets |
|
6.42
-58.15%
|
15.35
+341.76%
|
3.48
-61.32%
|
8.98
|
| Restricted Cash |
|
0.08
|
0.00
-100.00%
|
0.11
-45.15%
|
0.21
|
| Other Current Assets |
|
1.14
+49.87%
|
0.76
+702.11%
|
0.10
|
—
|
| Total Non Current Assets |
|
93.71
+169.24%
|
34.80
-4.00%
|
36.26
+545.91%
|
5.61
|
| Net PPE |
|
35.16
+4.36%
|
33.69
-4.35%
|
35.22
+687.13%
|
4.47
|
| Gross PPE |
|
43.15
+12.81%
|
38.25
+4.41%
|
36.63
+674.13%
|
4.73
|
| Accumulated Depreciation |
|
-7.99
-75.29%
|
-4.56
-223.65%
|
-1.41
-447.86%
|
-0.26
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
2.68
+0.00%
|
2.68
+0.00%
|
2.68
+406.62%
|
0.53
|
| Construction In Progress |
|
—
|
—
|
0.00
-100.00%
|
0.58
|
| Other Properties |
|
22.81
+27.10%
|
17.95
+9.72%
|
16.36
+355.20%
|
3.59
|
| Leases |
|
17.66
+0.21%
|
17.62
+0.15%
|
17.59
+56648.39%
|
0.03
|
| Goodwill And Other Intangible Assets |
|
50.96
|
0.00
|
—
|
—
|
| Other Non Current Assets |
|
7.59
+581.76%
|
1.11
+7.95%
|
1.03
-9.40%
|
1.14
|
| Total Liabilities Net Minority Interest |
|
110.64
+36.79%
|
80.89
-81.14%
|
428.87
+41.35%
|
303.41
|
| Current Liabilities |
|
73.32
+44.01%
|
50.91
+143.93%
|
20.87
+56.31%
|
13.35
|
| Payables And Accrued Expenses |
|
49.37
+18.70%
|
41.59
+206.56%
|
13.57
+60.24%
|
8.47
|
| Payables |
|
10.11
+5.01%
|
9.62
+760.82%
|
1.12
-35.00%
|
1.72
|
| Accounts Payable |
|
10.11
+5.01%
|
9.62
+760.82%
|
1.12
-35.00%
|
1.72
|
| Current Accrued Expenses |
|
39.26
+22.82%
|
31.96
+156.78%
|
12.45
+84.52%
|
6.75
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
17.82
+129.56%
|
7.76
+39.03%
|
5.58
+56.18%
|
3.58
|
| Current Debt And Capital Lease Obligation |
|
4.67
+199.94%
|
1.56
-9.48%
|
1.72
+31.30%
|
1.31
|
| Current Capital Lease Obligation |
|
4.67
+199.94%
|
1.56
-9.48%
|
1.72
+31.30%
|
1.31
|
| Current Deferred Liabilities |
|
1.46
|
0.00
|
—
|
—
|
| Current Deferred Revenue |
|
1.46
|
0.00
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
37.33
+24.51%
|
29.98
-92.65%
|
408.00
+40.66%
|
290.06
|
| Long Term Debt And Capital Lease Obligation |
|
32.24
+10.56%
|
29.16
-5.49%
|
30.86
+6479.96%
|
0.47
|
| Long Term Capital Lease Obligation |
|
32.24
+10.56%
|
29.16
-5.49%
|
30.86
+6479.96%
|
0.47
|
| Non Current Deferred Liabilities |
|
4.75
|
0.00
|
—
|
—
|
| Non Current Deferred Revenue |
|
2.61
|
0.00
|
—
|
—
|
| Non Current Deferred Taxes Liabilities |
|
2.14
|
0.00
|
—
|
—
|
| Other Non Current Liabilities |
|
0.33
-59.41%
|
0.81
-54.09%
|
1.77
-56.97%
|
4.12
|
| Preferred Securities Outside Stock Equity |
|
—
|
0.00
-100.00%
|
375.37
+31.49%
|
285.47
|
| Stockholders Equity |
|
301.30
+15.84%
|
260.10
+176.67%
|
-339.26
-73.76%
|
-195.24
|
| Common Stock Equity |
|
301.30
+15.84%
|
260.10
+176.67%
|
-339.26
-73.76%
|
-195.24
|
| Capital Stock |
|
0.01
+100.00%
|
0.01
+400.00%
|
0.00
+0.00%
|
0.00
|
| Common Stock |
|
0.01
+100.00%
|
0.01
+400.00%
|
0.00
+0.00%
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
—
|
| Share Issued |
|
104.71
+92.45%
|
54.41
+4.94%
|
51.84
+0.00%
|
51.84
|
| Ordinary Shares Number |
|
104.71
+92.45%
|
54.41
+4.94%
|
51.84
+0.00%
|
51.84
|
| Additional Paid In Capital |
|
1,202.97
+30.96%
|
918.61
+3566.37%
|
25.05
+76.33%
|
14.21
|
| Retained Earnings |
|
-901.88
-36.95%
|
-658.55
-80.76%
|
-364.32
-74.04%
|
-209.32
|
| Gains Losses Not Affecting Retained Earnings |
|
0.19
+370.00%
|
0.04
+1900.00%
|
0.00
+101.57%
|
-0.13
|
| Other Equity Adjustments |
|
0.19
+370.00%
|
0.04
+1900.00%
|
0.00
+101.57%
|
-0.13
|
| Total Equity Gross Minority Interest |
|
301.30
+15.84%
|
260.10
+176.67%
|
-339.26
-73.76%
|
-195.24
|
| Total Capitalization |
|
301.30
+15.84%
|
260.10
+176.67%
|
-339.26
-73.76%
|
-195.24
|
| Working Capital |
|
244.91
-4.06%
|
255.28
+685.81%
|
32.49
-63.58%
|
89.20
|
| Invested Capital |
|
301.30
+15.84%
|
260.10
+176.67%
|
-339.26
-73.76%
|
-195.24
|
| Total Debt |
|
36.91
+20.15%
|
30.72
-5.70%
|
32.58
+1731.37%
|
1.78
|
| Capital Lease Obligations |
|
36.91
+20.15%
|
30.72
-5.70%
|
32.58
+1731.37%
|
1.78
|
| Net Tangible Assets |
|
250.34
-3.75%
|
260.10
+176.67%
|
-339.26
-73.76%
|
-195.24
|
| Tangible Book Value |
|
250.34
-3.75%
|
260.10
+176.67%
|
-339.26
-73.76%
|
-195.24
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-369.52
-44.87%
|
-255.08
-96.25%
|
-129.97
-20.66%
|
-107.72
|
| Cash Flow From Continuing Operating Activities |
|
-369.52
-44.87%
|
-255.08
-96.25%
|
-129.97
-20.66%
|
-107.72
|
| Net Income From Continuing Operations |
|
-243.32
+17.30%
|
-294.23
-89.84%
|
-154.99
-38.47%
|
-111.93
|
| Depreciation Amortization Depletion |
|
3.50
+10.91%
|
3.15
+145.48%
|
1.28
+413.60%
|
0.25
|
| Depreciation And Amortization |
|
3.50
+10.91%
|
3.15
+145.48%
|
1.28
+413.60%
|
0.25
|
| Other Non Cash Items |
|
-186.21
-310443.33%
|
0.06
-97.01%
|
2.01
+111.58%
|
0.95
|
| Stock Based Compensation |
|
43.52
+123.69%
|
19.46
+125.59%
|
8.62
+44.71%
|
5.96
|
| Asset Impairment Charge |
|
0.53
|
0.00
-100.00%
|
0.56
|
0.00
|
| Operating Gains Losses |
|
—
|
5.41
+425.34%
|
1.03
|
—
|
| Gain Loss On Investment Securities |
|
—
|
5.41
+4442.86%
|
0.12
|
—
|
| Gain Loss On Sale Of PPE |
|
0.00
-100.00%
|
0.01
-99.45%
|
0.91
|
0.00
|
| Change In Working Capital |
|
17.76
+20.30%
|
14.76
+22.41%
|
12.06
+729.33%
|
-1.92
|
| Change In Prepaid Assets |
|
28.70
+310.53%
|
-13.63
-362.88%
|
5.19
+162.09%
|
-8.35
|
| Change In Payables And Accrued Expense |
|
-6.47
-121.40%
|
30.25
+331.17%
|
7.02
-3.32%
|
7.26
|
| Change In Accrued Expense |
|
8.12
-62.64%
|
21.75
+183.95%
|
7.66
+28.43%
|
5.96
|
| Change In Payable |
|
-14.60
-271.61%
|
8.51
+1424.92%
|
-0.64
-149.61%
|
1.29
|
| Change In Account Payable |
|
-6.04
-170.96%
|
8.51
+1424.92%
|
-0.64
-149.61%
|
1.29
|
| Change In Other Working Capital |
|
4.07
|
—
|
—
|
—
|
| Change In Other Current Assets |
|
-5.54
|
0.00
|
—
|
—
|
| Change In Other Current Liabilities |
|
-3.00
-61.73%
|
-1.86
-1190.28%
|
-0.14
+82.44%
|
-0.82
|
| Investing Cash Flow |
|
287.88
+352.99%
|
-113.79
-288.17%
|
60.47
+187.96%
|
-68.75
|
| Cash Flow From Continuing Investing Activities |
|
287.88
+352.99%
|
-113.79
-288.17%
|
60.47
+187.96%
|
-68.75
|
| Net PPE Purchase And Sale |
|
-0.65
+62.30%
|
-1.73
+61.50%
|
-4.50
-86.99%
|
-2.41
|
| Purchase Of PPE |
|
-0.65
+62.30%
|
-1.73
+61.50%
|
-4.50
-86.99%
|
-2.41
|
| Capital Expenditure |
|
-0.65
+62.30%
|
-1.73
+61.50%
|
-4.50
-86.99%
|
-2.41
|
| Net Investment Purchase And Sale |
|
238.79
+313.09%
|
-112.06
-272.47%
|
64.97
+197.93%
|
-66.34
|
| Purchase Of Investment |
|
-209.17
+12.87%
|
-240.06
-2028.36%
|
-11.28
+94.61%
|
-209.07
|
| Sale Of Investment |
|
447.95
+249.96%
|
128.00
+67.87%
|
76.25
-46.58%
|
142.73
|
| Net Other Investing Changes |
|
49.74
|
—
|
—
|
—
|
| Financing Cash Flow |
|
2.07
-99.58%
|
492.37
+449.01%
|
89.68
-11.75%
|
101.63
|
| Cash Flow From Continuing Financing Activities |
|
2.07
-99.58%
|
492.37
+449.01%
|
89.68
-11.75%
|
101.63
|
| Net Common Stock Issuance |
|
0.00
-100.00%
|
193.32
|
0.00
|
—
|
| Common Stock Payments |
|
—
|
—
|
0.00
|
—
|
| Repurchase Of Capital Stock |
|
—
|
—
|
0.00
|
—
|
| Proceeds From Stock Option Exercised |
|
2.07
+250.34%
|
0.59
+51.67%
|
0.39
-77.57%
|
1.73
|
| Net Other Financing Charges |
|
—
|
40.00
+8347.42%
|
-0.48
|
—
|
| Changes In Cash |
|
-79.58
-164.44%
|
123.50
+512.02%
|
20.18
+126.96%
|
-74.85
|
| Beginning Cash Position |
|
170.63
+262.02%
|
47.13
+74.86%
|
26.95
-73.52%
|
101.80
|
| End Cash Position |
|
91.05
-46.64%
|
170.63
+262.02%
|
47.13
+74.86%
|
26.95
|
| Free Cash Flow |
|
-370.18
-44.14%
|
-256.81
-90.97%
|
-134.47
-22.11%
|
-110.13
|
| Amortization Of Securities |
|
-5.30
-43.77%
|
-3.69
-577.39%
|
-0.54
+47.49%
|
-1.04
|
| Change In Income Tax Payable |
|
-8.56
|
0.00
|
—
|
—
|
| Change In Tax Payable |
|
-8.56
|
0.00
|
—
|
—
|
| Common Stock Issuance |
|
0.00
-100.00%
|
193.32
|
—
|
—
|
| Issuance Of Capital Stock |
|
0.00
-100.00%
|
451.78
+403.22%
|
89.78
-10.13%
|
99.89
|
| Net Preferred Stock Issuance |
|
0.00
-100.00%
|
258.46
+187.89%
|
89.78
-10.13%
|
99.89
|
| Preferred Stock Issuance |
|
0.00
-100.00%
|
258.46
+187.89%
|
89.78
-10.13%
|
99.89
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-03 View
- 42026-04-03 View
- 42026-04-03 View
- 8-K2026-03-30 View
- 10-K2026-03-19 View
- 8-K2026-03-19 View
- 42026-01-28 View
- 42026-01-28 View
- 42026-01-28 View
- 42026-01-28 View
- 42026-01-28 View
- 42026-01-28 View
- 42026-01-28 View
- 42026-01-13 View
- 42026-01-12 View
- 42026-01-12 View
- 42026-01-12 View
- 8-K2026-01-09 View
- 8-K2026-01-06 View
- 8-K2026-01-02 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|